Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Interleukin-2 (IL-2) is a cytokine crucial for immune responses.
• Understanding tumor rejection mechanisms is vital for cancer therapy development.
• Gene transfection offers a method to modulate tumor microenvironments.

Purpose of the Study:

• To investigate the role of in situ interleukin-2 (IL-2) gene expression in mouse renal cell carcinoma (RenCa) rejection.
• To elucidate the cellular mechanisms underlying IL-2-mediated tumor suppression.
• To explore the potential for acquired immunity following IL-2 gene therapy.

Main Methods:

• Transfection of RenCa cells with the IL-2 gene (RenCa/IL-2Hi).
• Implantation of RenCa/IL-2Hi in syngeneic and athymic nude mice.
• Depletion of natural killer (NK) cells using anti-asialo GM1 antibody.
• Histological analysis of tumor tissues.
• Co-administration of Bacillus Calmette Guerin (BCG) with RenCa/IL-2Hi.

Main Results:

• RenCa/IL-2Hi demonstrated significantly retarded tumor growth in syngeneic hosts.
• Tumor growth retardation persisted in athymic nude mice, even after NK cell depletion.
• Histological examination revealed non-specific inflammatory changes within RenCa/IL-2Hi tumors.
• Co-injection with BCG amplified the anti-tumor effects.
• Mice rejecting RenCa/IL-2Hi developed immunity against parental RenCa.

Conclusions:

• In situ IL-2 production induces tumor rejection through non-specific inflammatory responses, independent of T cells and NK cells.
• The findings suggest a potential role for memory T cells in acquired immunity against the tumor post-rejection.
• IL-2 gene therapy holds promise for cancer treatment by stimulating localized anti-tumor inflammation.